News Releases

2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
1
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
2
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
3
2021-02/07
Interim Analysis Results of the Phase I clinical trial of UBIA’s COVID-19 vaccine UB-612
4
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
5
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
6
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
7
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
8
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
9
2021-10/18
United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621
1
2021-08/18
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
2
2021-07/15
United BioPharma Received IND Approval from China NMPA for a larger Phase 2 Trial with multi-dosing UB-621 to demonstrate optimal clinical efficacy in treatment of Recurrent Genital Herpes
3
2021-02/07
Interim Analysis Results of the Phase I clinical trial of UBIA’s COVID-19 vaccine UB-612
4
2020-12/10
United BioPharma won the “2020 National Talent Development Award''
5
2020-11/11
United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes
6
2020-09/28
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
7
2020-08/21
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
8
2020-08/05
United BioPharma Received Approval from Taiwan FDA for a Phase 1 Trial with UB-421 Subcutaneous Formulation in HIV-1 Infected Patients
9